Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Unicar-Therapy Publishes Positive Data for Dual-Target CAR T-cell Leukemia Therapy

publication date: May 30, 2023

Shanghai Unicar-Therapy published Phase I/II data showing its sequential CD19/CD22 dual-target CAR T-cell therapies outperformed single CD19 CAR-T candidates in patients with B-cell acute lymphoblastic leukemia. In 219 patients, the single CD19 group’s complete response was 83%, the tandem CD19/CD22 was 98%, and the sequential CD19/CD22 was 95%. Unicar pointed out that single CD19 CAR-T therapies, although they may be effective initially, are prone to relapse. TSingle CD19 patients had a two-year overall survival of 59%, while the two dual therapy patients’ two-year OS rate was 78%. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital